Physician profile
Gerardo Posada
NPI 1073672861
$5,090.32
in general payments reported to CMS, 2019-2025
9 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,232 · 2020: $246 · 2021: $490 · 2022: $320 · 2023: $465 · 2024: $213 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,288.41 | 2019-2021 | |
| Alkermes, INC. | $839.85 | 2019-2023 | Aristada, Aristada Initio |
| Allergan, INC. | $734.33 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $719.37 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $463.43 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $424.31 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $375.04 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $124.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $120.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerardo Posada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.